The drug Plavix improves the survival chances of people with heart failure, according to a study
Researchers say it improves the survival chances of people with heart failure, who had previously suffered a heart attack but had not had angioplasty treatment to clear their arteries.
The Danish study of Plavix, a Bristol-Myers Squibb drug also widely referred to as clopidogrel, is of “unquestionable practical importance”, according to Victor Serebruany at the HeartDrug Research Labs at John Hopkins University in the US.
The merit of using clopidogrel for heart failure has long been debated.
The results of the study are published in the Journal of the American College of Cardiology.
After 18 months, 32.2% of high-risk patients in the group not treated with Plavix died versus 28.1%in the group that did receive it.
The statistics could have “considerable clinical impact,” the researchers wrote, urging a better understanding of the benefits of using the drug.